Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP: Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant. 1994, 9: 1136-1142.
Article
CAS
PubMed
Google Scholar
Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998, 32: S112-S119.
Article
CAS
PubMed
Google Scholar
Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT: Controlling the epidemic of cardiovascular disease in chronic renal disease. National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998, 32: 853-906.
Article
CAS
PubMed
Google Scholar
Parfrey PS: Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant. 2000, 15 (Suppl 5): 58-68. 10.1093/ndt/15.suppl_5.58.
Article
PubMed
Google Scholar
US Renal Data System: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2000. Annual Data Report. 2000, Bethesda, MD
Google Scholar
Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974, 290: 697-701.
Article
CAS
PubMed
Google Scholar
Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994, 344: 1383-1389.
Google Scholar
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995, 333: 1301-1307. 10.1056/NEJM199511163332001.
Article
CAS
PubMed
Google Scholar
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med. 1996, 335: 1001-1009. 10.1056/NEJM199610033351401.
Article
CAS
Google Scholar
Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 1998, 279: 1615-1622. 10.1001/jama.279.20.1615.
Article
CAS
PubMed
Google Scholar
The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Eng J Med. 1998, 339: 1349-1357. 10.1056/NEJM199811053391902.
Article
Google Scholar
Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002, 360: 7-22. 10.1016/S0140-6736(02)09327-3.
Article
Google Scholar
Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, MacFlarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002, 360: 1623-1630. 10.1016/S0140-6736(02)11600-X.
Article
CAS
PubMed
Google Scholar
Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, Obrien E, Östergren J, for the ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003, 361: 1149-1158. 10.1016/S0140-6736(03)12948-0.
Article
CAS
PubMed
Google Scholar
Laufs U: Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol. 2003, 58: 719-731.
CAS
PubMed
Google Scholar
Shoji T, Nishizawa Y, Kawagishi T, Tanka M, Kawasaki K, Tabata T, Inoue T, Morii H: Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis. 1997, 131: 229-236. 10.1016/S0021-9150(97)00054-3.
Article
CAS
PubMed
Google Scholar
Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T, Inoue T, Morii H: Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol. 1998, 9: 1277-1284.
CAS
PubMed
Google Scholar
Baigent C, Landry M: Study of Heart and Renal Protection (SHARP). Kidney Int. 2003, 63 (Suppl 84): 207-210. 10.1046/j.1523-1755.63.s84.4.x.
Article
Google Scholar
Baigent C, Burbury K, Wheeler D: Premature cardiovascular disease in chronic renal failure. Lancet. 2000, 356: 147-152. 10.1016/S0140-6736(00)02456-9.
Article
CAS
PubMed
Google Scholar
Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004, 291: 451-459. 10.1001/jama.291.4.451.
Article
CAS
PubMed
Google Scholar
Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002, 61: 297-304. 10.1046/j.1523-1755.2002.00109.x.
Article
CAS
PubMed
Google Scholar
Kidney Disease Outcomes Quality Initiative: Managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003, 41 (Suppl 3): S1-S91.
Google Scholar
Wanner C, Krane V, Marz W, Olschewski M, Asmus HG, Kramer W, Kuhn KW, Kutemeyer H, Mann JF, Ruf G, Ritz E, Deutsche Diabetes-Dialyse-Studie (4D) Study Group: Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney Blood Press Res. 2004, 27: 259-266. 10.1159/000080241.
Article
CAS
PubMed
Google Scholar
Wanner C: Results of a randomized controlled trial with atorvastatin in dialyzed diabetic patients (4D trial). Presented at the annual meeting of the American Society of Nephrology. St Louis, Missouri, USA, 29 October 2004
Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A: Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol. 2003, 91: 3C-10C. 10.1016/S0002-9149(03)00003-1.
Article
CAS
PubMed
Google Scholar
Chapman MJ, Caslake M, Packard C, McTaggart F: New dimension of statin action on apoB atherogenicity. Clin Cardiol. 2003, 26 (Suppl I): I7-I10.
Article
PubMed
Google Scholar
Brewer HB: Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol. 2003, 92 (Suppl 2): 23-29. 10.1016/S0002-9149(03)00779-3.
Article
Google Scholar
Cox D: Regression models and life tablets (with discussion). J Royal Stat Soc. 1972, 74: 187-220.
Google Scholar
Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988, 260: 1917-1921. 10.1001/jama.260.13.1917.
Article
CAS
PubMed
Google Scholar
Campos H, Genest JJ, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, Wilson PW, Schaefer EJ: Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 1992, 12: 187-195.
Article
CAS
PubMed
Google Scholar
Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després JP: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation. 1997, 95: 69-75.
Article
CAS
PubMed
Google Scholar
Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stamfer MJ, Pfeffer MA, Braunwald E: VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol Recurrent Events (CARE) trial. Circulation. 2000, 102: 1886-1892.
Article
CAS
PubMed
Google Scholar
O'Neal D, Lee P, Murphy B, Best J: Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis. 1996, 27: 84-91.
Article
PubMed
Google Scholar
Königer M, Quaschning T, Wanner C, Schollmeyer P, Krämer-Guth A: Abnormalities in lipoprotein metabolism in hemodialysis patients. Kidney Int. 1999, 56 (Suppl 71): S248-S250. 10.1046/j.1523-1755.1999.07166.x.
Article
Google Scholar
Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ: Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis. 2000, 35: 852-862.
Article
CAS
PubMed
Google Scholar
Wanner C, Quaschning T: Dyslipidemia and renal disease: pathogenesis and clinical consequences. Curr Opin Nephrol Hypertens. 2001, 10: 195-201.
Article
CAS
PubMed
Google Scholar
Fytili CI, Progia EG, Panagoustsos SA, Thodis ED, Passadakis PS, Sombolos KI, Vargemezis VA: Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients. Ren Fail. 2002, 24: 623-630. 10.1081/JDI-120013966.
Article
CAS
PubMed
Google Scholar
Wanner C, Horl WH, Luley CH, Wieland H: Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney Int. 1991, 39: 754-760.
Article
CAS
PubMed
Google Scholar
Nishizawa Y, Shoji T, Emoto M, Kawasaki K, Konishi T, Tabata T, Inoue T, Morii H: Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients. Clin Nephrol. 1995, 43: 268-277.
CAS
PubMed
Google Scholar
Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H: Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. Kidney Int. 1999, 56 (Suppl 71): S134-S136. 10.1046/j.1523-1755.1999.07133.x.
Article
Google Scholar
Nishikawa O, Mune M, Miyano M, Nishide T, Maeda A, Kimura K, Takahashi T, Kishino M, Tone Y, Otani H, Ogawa A, Maeda T, Yukawa S: Effect of simvastatin on the lipid profile of hemodialysis patients. Kidney Int. 1999, 56 (Suppl 71): S219-S221. 10.1046/j.1523-1755.1999.07157.x.
Article
Google Scholar
Saltissi D, Morgan C, Rogby RJ, Westhuyzen J: Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis. 2002, 39: 283-290.
Article
CAS
PubMed
Google Scholar
Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR, Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003, 361: 2024-2031. 10.1016/S0140-6736(03)13638-0.
Article
CAS
PubMed
Google Scholar
Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW: Comparison of the efficacy and safety of rosuvastatin versus atorvasatatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003, 92: 152-160. 10.1016/S0002-9149(03)00530-7.
Article
CAS
PubMed
Google Scholar
Olsson AG, McTaggart F, Raza A: Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2002, 20: 303-328.
Article
CAS
PubMed
Google Scholar
Locatelli F, Canaud B, Eckardt K-U, Stenvinkel P, Wanner C, Zoccali C: Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 2003, 18: 1272-1280. 10.1093/ndt/gfg074.
Article
CAS
PubMed
Google Scholar
Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B: Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol. 2001, 12: 2747-2752.
CAS
PubMed
Google Scholar
Rosenson RS: Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis. 2004, 173: 1-12. 10.1016/S0021-9150(03)00239-9.
Article
CAS
PubMed
Google Scholar
Annuk M, Lind L, Linde T, Fellström B: Impaired endothelium-dependent vasodilation in renal failure in humans. Nephrol Dial Transplant. 2001, 16: 302-306. 10.1093/ndt/16.2.302.
Article
CAS
PubMed
Google Scholar
Stalker TJ, Lefer AM, Scalia R: A new HMG-Co A reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol. 2001, 133: 406-412. 10.1038/sj.bjp.0704070.
Article
CAS
PubMed
PubMed Central
Google Scholar
Foley RN: Clinical epidemiology of cardiac disease in dialysis patients: ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial. 2003, 16: 111-117. 10.1046/j.1525-139X.2003.160271.x.
Article
PubMed
Google Scholar
Su SF, Hsiao CL, Chu CW, Lee BC, Lee TM: Effects of pravastatin on left ventricular mass in patients with hyperlipidaemia and essential hypertension. Am J Cardiol. 2000, 86: 514-518. 10.1016/S0002-9149(00)01004-3.
Article
CAS
PubMed
Google Scholar
Kjekshus J, Pederson TR, Olsson AG, Faergeman O, Pyörälä L: The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997, 3: 249-254. 10.1016/S1071-9164(97)90022-1.
Article
CAS
PubMed
Google Scholar